scholarly journals Development of a Cruciferous Vegetable Intervention to Prevent Cancer Recurrence in Non-Muscle Invasive Bladder Cancer Survivors (Preprint)

2021 ◽  
Author(s):  
Karen Yeary ◽  
Nikia Clark ◽  
Frances Saad-Harfouche ◽  
Deborah Erwin ◽  
Margaret Kuliszewski ◽  
...  

BACKGROUND Bladder cancer is one of the top 10 most common cancers in the US. Most bladder cancer (70-80%) is diagnosed at early stages as non-muscle invasive bladder cancer (NMIBC), which can be removed surgically. However, 50-80% of NMIBC recurs within 5 years, and 15-30% progresses with poor survival. Current treatment is limited and expensive. A wealth of preclinical and epidemiologic evidence suggests that dietary isothiocyanates (ITCs) in cruciferous vegetables (Cruciferae) could be a novel, non-invasive, and cost-effective strategy to control NMIBC recurrence and progression. Yet a scalable dietary intervention that increases ITC exposure through Cruciferae intake in NMIBC survivors has not been developed. OBJECTIVE This paper will describe a systematic process through which a dietary intervention for bladder cancer survivors was developed that can serve as a model for others who aim to develop evidence-based behavioral interventions for cancer prevention. METHODS We used a systematic process to adapt evidence-based dietary interventions into a Cruciferae intervention for NMIBC survivors. We 1) identified relevant factors, evidence-based behavioral techniques, and behavioral theory constructs used to increase cruciferae intake in NMIBC survivors; 2) used the PEN-3 model to review the intervention’s components (e.g. saliency of behavioral messages); 3) administered the revised intervention to community partners for their feedback; and 4) refined the intervention based on Step 3. RESULTS We developed a multi-component intervention for NMIBC survivors consisting of a magazine, tracking book, a live phone-call script, and interactive voice messages (IVR). Entitled “POW-R Health: Power to Redefine Your Health”, the intervention incorporated findings from our adaptation process to ensure saliency to NMIBC survivors. CONCLUSIONS This is the first evidence-based, theoretically grounded dietary intervention developed to reduce bladder recurrence in NMIBC survivors using a systematic process for community adaptation. This study provides a model for others who aim to develop behavioral, community-relevant interventions for cancer prevention/control, with the overall goal of wide-scale implementation and dissemination.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 473-473
Author(s):  
Woodson Smelser ◽  
Vassili Glazyrine ◽  
Brian Barnes ◽  
Abigail Stanley ◽  
Misty Bechtel ◽  
...  

473 Background: Patients with diabetes are at greater risk for bladder cancer (BC) as well as disease recurrence and progression. Even after controlling for clinical and pathologic risk factors, DM confers a 2x greater risk of recurrence and 9x greater risk of progression. We hypothesize that utilizing a carbohydrate restricted (CR) diet ( < 130 grams/day) to decrease the bioavailability of glucose in patients with DM and BC, a “Warburg-like” tumor, has potential therapeutic benefit. We designed a study to assess the feasibility of a CR diet in patients with (pre)diabetes and non-muscle invasive bladder cancer receiving BCG therapy. Methods: This is a pilot study of 5 (pre)diabetic patients (defined as HgbA1c > 5.7) with NMIBC receiving BCG and maintenance. A CR diet ( < 130 g/day) was supplied for the first 12 weeks through a meal delivery service. Patients received weekly coaching with a nutritionist for 6 weeks during induction BCG and at the 3 month surveillance cystoscopy with dietary and activity goals implemented. Patients had laboratory evaluation at baseline and at 3 month intervals. Patients tracked their diet. Two (1 weekday, 1 weekend day) unannounced 24 hour diet recalls were obtained to monitor compliance. Dietary compliance was defined as < 130 grams/day of carbohydrate intake. Results: Between 09/2016 and 05/2017, 5 patients were enrolled. Mean age was 66.2 years (Range 59-74). Three patients had diabetes and two patients had pre-diabetes. Two patients had CIS, 1 patient had high-grade Ta, and 2 patients had high-grade T1 disease. Mean baseline hemoglobin A1c was 7.6% (Range 5.9-11.8). Mean bodyweight and BMI were 92 kg (Range 66-105) and 28.2 (Range 23.1- 31.3) respectively. Regarding compliance, 4/5 (80%) patients completed dietary logs and weekly labs. Three patients (60%) achieved their goal of < 130 grams carbohydrates/day on 24-hour dietary recall. Average 3-month HbA1c improved from 7.6% to 6.6% (Range 5.6-7.9). Conclusions: Eighty percent of patients completed dietary logs for the first three months of the trial; 60% achieved compliance with the CR diet. These data demonstrate the feasibility of a dietary intervention utilizing CR in patients with high-grade NMIBC undergoing BCG. Clinical trial information: NCT02716623.


2020 ◽  
Vol 18 (7.5) ◽  
pp. 973-976
Author(s):  
Philippe E. Spiess

The current NCCN Guidelines for Bladder Cancer reflect the most up-to-date, evidence-based data relating to the evaluation and management of non–muscle-invasive bladder cancer (NMIBC). The most notable revision to the guidelines this year is the addition of pembrolizumab for a high-risk subset of patients not responding to bacillus Calmette-Guérin (BCG). It is anticipated that current BCG shortages will offer unique opportunities to promote and enhance clinical trials for patients with bladder cancer. Recent efforts to more precisely define BCG-unresponsive disease (adopted by the FDA) have been critical to standardizing definitions and evaluating the efficacy of clinical trials in bladder cancer.


2019 ◽  
Vol 42 (3) ◽  
pp. E21-E33 ◽  
Author(s):  
Ahrang Jung ◽  
Matthew E. Nielsen ◽  
Jamie L. Crandell ◽  
Mary H. Palmer ◽  
Ashley Leak Bryant ◽  
...  

Author(s):  
Jessica Marinaro ◽  
Alexander Zeymo ◽  
Jillian Egan ◽  
Filipe Carvalho ◽  
Ross Krasnow ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document